Published in J Neurochem on November 01, 2007
Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci (2009) 1.59
Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness. Mol Cancer (2009) 0.88
Region-specific roles of the corticotropin-releasing factor-urocortin system in stress. Nat Rev Neurosci (2016) 0.85
Anxiolytic-like effects of antisauvagine-30 in mice are not mediated by CRF2 receptors. PLoS One (2013) 0.80
Desensitization of human CRF2(a) receptor signaling governed by agonist potency and βarrestin2 recruitment. Regul Pept (2013) 0.78
Dopamine D1 and corticotrophin-releasing hormone type-2α receptors assemble into functionally interacting complexes in living cells. Br J Pharmacol (2014) 0.77
CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol (2004) 5.21
Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A (2001) 3.23
Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci (1995) 3.04
Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A (2001) 2.87
Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med (2001) 2.33
Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets (2006) 1.97
The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci (2002) 1.84
International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev (2003) 1.79
Family-B G-protein-coupled receptors. Genome Biol (2001) 1.75
Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol (1999) 1.63
Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett (1993) 1.48
Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci (1997) 1.47
Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci (1999) 1.46
Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci U S A (1995) 1.45
Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther (1999) 1.28
Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes. Psychopharmacology (Berl) (2006) 1.24
Cloning and characterization of human urocortin. Endocrinology (1996) 1.23
Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci U S A (1998) 1.23
Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol (1998) 1.17
Carboxyl-terminal and intracellular loop sites for CRF1 receptor phosphorylation and beta-arrestin-2 recruitment: a mechanism regulating stress and anxiety responses. Am J Physiol Regul Integr Comp Physiol (2007) 1.12
Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J Med Chem (1996) 1.03
GRK3 regulation during CRF- and urocortin-induced CRF1 receptor desensitization. Biochem Biophys Res Commun (2002) 1.00
N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants. J Neuroendocrinol (1999) 1.00
Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology (2003) 1.00
Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-- an update. CNS Neurol Disord Drug Targets (2006) 0.96
125I-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors. Neuropharmacology (2001) 0.95
Inhibition of corticotropin releasing hormone type-1 receptor translation by an upstream AUG triplet in the 5' untranslated region. Mol Pharmacol (2001) 0.92
GRK3 mediates desensitization of CRF1 receptors: a potential mechanism regulating stress adaptation. Am J Physiol Regul Integr Comp Physiol (2001) 0.90
Mediation of corticotropin releasing factor type 1 receptor phosphorylation and desensitization by protein kinase C: a possible role in stress adaptation. J Pharmacol Exp Ther (2003) 0.90
Promoter analysis of human corticotropin-releasing factor (CRF) type 1 receptor and regulation by CRF and urocortin. Endocrinology (2004) 0.90
The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets (2005) 0.89
Synthesis and characterization of a photoactivatable analog of corticotropin-releasing factor for specific receptor labeling. Proc Natl Acad Sci U S A (1996) 0.88
Functional characterization of corticotropin-releasing factor type 1 receptor endogenously expressed in human embryonic kidney 293 cells. Eur J Pharmacol (2000) 0.88
Differential regulation of corticotropin-releasing factor1 receptor expression by stress and agonist treatments in brain and cultured cells. Mol Pharmacol (1996) 0.87
Functional CRF receptors in BON cells stimulate serotonin release. Biochem Pharmacol (2006) 0.86
Glucocorticoid regulation of corticotropin-releasing factor1 receptor expression in pituitary-derived AtT-20 cells. Mol Pharmacol (1997) 0.86
Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor. J Neurochem (1997) 0.85
Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases. J Neurochem (2003) 0.85
Cell-type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: phospholipase C-mediated responses in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells. Biochem Pharmacol (2004) 0.84
Corticotropin-releasing factor (CRF) and the urocortins differentially regulate catecholamine secretion in human and rat adrenals, in a CRF receptor type-specific manner. Endocrinology (2006) 0.84
Five amino acids of the Xenopus laevis CRF (corticotropin-releasing factor) type 2 receptor mediate differential binding of CRF ligands in comparison with its human counterpart. Mol Pharmacol (2002) 0.83
Regulation of corticotropin-releasing factor receptor function in human Y-79 retinoblastoma cells: rapid and reversible homologous desensitization but prolonged recovery. J Neurochem (1997) 0.83
Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from Tupaia belangeri. J Neuroendocrinol (1999) 0.83
Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences. J Pharmacol Exp Ther (2001) 0.82
Molecular cloning and functional expression of the mouse CRF2(a) receptor splice variant. Regul Pept (2004) 0.81
Urocortin 2 induces tyrosine hydroxylase phosphorylation in PC12 cells. Biochem Biophys Res Commun (2005) 0.80
Characterization of the human corticotropin-releasing factor2(a) receptor promoter: regulation by glucocorticoids and the cyclic adenosine 5'-monophosphate pathway. Endocrinology (2004) 0.79
Functional corticotropin-releasing factor receptors in human neuroblastoma cells. Brain Res (1996) 0.78
Corticotropin-releasing factor induces phosphorylation of phospholipase C-gamma at tyrosine residues via its receptor 2beta in human epidermoid A-431 cells. Eur J Pharmacol (1998) 0.77
Genetic variation in human NPY expression affects stress response and emotion. Nature (2008) 2.65
Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets (2006) 1.97
The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci (2002) 1.84
International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev (2003) 1.79
Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci (2009) 1.59
A two-state model of antagonist-AT1 receptor interaction: further support by binding studies at low temperature. Biochem Pharmacol (2003) 1.40
Age-related changes of circadian rhythms and sleep-wake cycles. J Am Geriatr Soc (2003) 1.33
The association of posttraumatic stress disorder and metabolic syndrome: a study of increased health risk in veterans. BMC Med (2009) 1.26
Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci (2004) 1.26
Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol Psychiatry (2002) 1.24
Abnormal nocturnal melatonin secretion and disordered sleep in abstinent alcoholics. Biol Psychiatry (2003) 1.15
Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br J Pharmacol (2010) 1.13
Blocking melanin-concentrating hormone MCH1 receptor affects rat sleep-wake architecture. Eur J Pharmacol (2007) 1.13
Carboxyl-terminal and intracellular loop sites for CRF1 receptor phosphorylation and beta-arrestin-2 recruitment: a mechanism regulating stress and anxiety responses. Am J Physiol Regul Integr Comp Physiol (2007) 1.12
Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) (2003) 1.11
A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. Br J Pharmacol (2014) 1.09
Salivary cortisol and prefrontal cortical thickness in middle-aged men: A twin study. Neuroimage (2010) 1.09
Cross-sectional and 35-year longitudinal assessment of salivary cortisol and cognitive functioning: the Vietnam Era twin study of aging. Psychoneuroendocrinology (2011) 1.08
Genetic and environmental influences on cortisol regulation across days and contexts in middle-aged men. Behav Genet (2010) 1.03
CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology (2008) 1.02
GRK3 regulation during CRF- and urocortin-induced CRF1 receptor desensitization. Biochem Biophys Res Commun (2002) 1.00
Plasma melatonin circadian rhythm disturbances during pregnancy and postpartum in depressed women and women with personal or family histories of depression. Am J Psychiatry (2008) 0.97
Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-- an update. CNS Neurol Disord Drug Targets (2006) 0.96
Molecular mechanisms of corticotropin-releasing factor receptor-induced calcium signaling. Mol Pharmacol (2008) 0.95
Agonist induction and conformational selection during activation of a G-protein-coupled receptor. Trends Pharmacol Sci (2003) 0.94
Therapeutic potential of group III metabotropic glutamate receptors. Curr Med Chem (2008) 0.94
Increased melatonin and delayed offset in menopausal depression: role of years past menopause, follicle-stimulating hormone, sleep end time, and body mass index. J Clin Endocrinol Metab (2007) 0.94
Trauma exposure rather than posttraumatic stress disorder is associated with reduced baseline plasma neuropeptide-Y levels. Biol Psychiatry (2003) 0.93
Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy. J Pharmacol Exp Ther (2007) 0.93
Synthesis and biological activities of conformationally restricted cyclopentenyl-glutamate analogues. J Org Chem (2002) 0.91
Mediation of corticotropin releasing factor type 1 receptor phosphorylation and desensitization by protein kinase C: a possible role in stress adaptation. J Pharmacol Exp Ther (2003) 0.90
Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy. Neuropharmacology (2011) 0.88
Genetic influences on hippocampal volume differ as a function of testosterone level in middle-aged men. Neuroimage (2011) 0.88
Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. J Pharmacol Exp Ther (2013) 0.88
Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N-and C-terminal residues of angiotensin II during AT1 receptor activation. J Biol Chem (2002) 0.87
Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail Rev (2007) 0.86
Pressor and renal hemodynamic effects of the novel angiotensin A peptide are angiotensin II type 1A receptor dependent. Hypertension (2011) 0.85
In vitro inhibition of [3H]-angiotensin II binding on the human AT1 receptor by proanthocyanidins from Guazuma ulmifolia bark. Planta Med (2002) 0.85
Novel hexahydrospiro[piperidine-4,1'-pyrrolo[3,4-c]pyrroles]: highly selective small-molecule nociceptin/orphanin FQ receptor agonists. J Med Chem (2003) 0.85
Cell-type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: phospholipase C-mediated responses in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells. Biochem Pharmacol (2004) 0.84
Further evidence for association of GRK3 to bipolar disorder suggests a second disease mutation. Psychiatr Genet (2007) 0.84
Late, but not early, wake therapy reduces morning plasma melatonin: relationship to mood in Premenstrual Dysphoric Disorder. Psychiatry Res (2008) 0.84
Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP). J Med Chem (2010) 0.84
KLHL12-mediated ubiquitination of the dopamine D4 receptor does not target the receptor for degradation. Cell Signal (2010) 0.83
Corticotropin releasing factor-induced ERK phosphorylation in AtT20 cells occurs via a cAMP-dependent mechanism requiring EPAC2. Neuropharmacology (2009) 0.83
Nociceptive and behavioural sensitisation by protein kinase Cepsilon signalling in the CNS. J Neurochem (2007) 0.83
Five amino acids of the Xenopus laevis CRF (corticotropin-releasing factor) type 2 receptor mediate differential binding of CRF ligands in comparison with its human counterpart. Mol Pharmacol (2002) 0.83
Endogenous cystinyl aminopeptidase in Chinese hamster ovary cells: characterization by [125I]Ang IV binding and catalytic activity. Biochem Pharmacol (2004) 0.83
Structure-activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands. J Med Chem (2004) 0.82
Increased sensitivity to light-induced melatonin suppression in premenstrual dysphoric disorder. Chronobiol Int (2010) 0.82
Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur J Pharmacol (2008) 0.82
Antagonist-radioligand binding to D2L-receptors in intact cells. Biochem Pharmacol (2008) 0.82
Urocortins of the South African clawed frog, Xenopus laevis: conservation of structure and function in tetrapod evolution. Endocrinology (2005) 0.81
Synergistic modulation of cystinyl aminopeptidase by divalent cation chelators. Biochem Pharmacol (2004) 0.81
Role of dopamine D1 and D2 receptors in CRF-induced disruption of sensorimotor gating. Pharmacol Biochem Behav (2007) 0.81
Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe. Psychoneuroendocrinology (2013) 0.80
Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors. Biochem Pharmacol (2003) 0.80
Inhibitory activity on binding of specific ligands to the human angiotensin II AT(1) and endothelin 1 ET(A) receptors: bioactive benzo[c]phenanthridine alkaloids from the root of Bocconia frutescens. Planta Med (2002) 0.80
Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concentrating hormone antagonists. J Med Chem (2009) 0.79
Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells. Eur J Pharmacol (2005) 0.79
Angiotensin AT4 receptor ligand interaction with cystinyl aminopeptidase and aminopeptidase N: [125I]Angiotensin IV only binds to the cystinyl aminopeptidase apo-enzyme. Eur J Pharmacol (2006) 0.79
Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Bioorg Med Chem (2008) 0.79
Effect of saponin and filipin on antagonist binding to AT 1 receptors in intact cells. Biochem Pharmacol (2004) 0.79
Involvement of the AT1 receptor subtype in the effects of angiotensin IV and LVV-haemorphin 7 on hippocampal neurotransmitter levels and spatial working memory. J Neurochem (2009) 0.79
Desensitization of human CRF2(a) receptor signaling governed by agonist potency and βarrestin2 recruitment. Regul Pept (2013) 0.78
The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues. J Med Chem (2009) 0.78
Unravelling the complex dissociation of [(3)H]-rimonabant from plated CB(1) cannabinoid receptor-expressing cells. Fundam Clin Pharmacol (2009) 0.78
Binding properties of antagonists to cannabinoid receptors in intact cells. Fundam Clin Pharmacol (2011) 0.78
Synergistic inhibition of the enzymatic activity of aminopeptidase N by divalent metal ion chelators. Fundam Clin Pharmacol (2006) 0.78
Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat. J Neurochem (2004) 0.78
Cyclic insulin-regulated aminopeptidase (IRAP)/AT4 receptor ligands. J Pept Sci (2006) 0.78
Weak evidence of bright light effects on human LH and FSH. J Circadian Rhythms (2010) 0.78
Distinct binding properties of the AT(1) receptor antagonist [(3)H]candesartan to intact cells and membrane preparations. Biochem Pharmacol (2002) 0.77
Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity. Peptides (2002) 0.77
Antagonist-D2S-dopamine receptor interactions in intact recombinant Chinese hamster ovary cells [corrected]. Fundam Clin Pharmacol (2009) 0.77
Beta-homo-amino acid scan of angiotensin IV. J Med Chem (2008) 0.77
Involvement of insulin-regulated aminopeptidase and/or aminopeptidase N in the angiotensin IV-induced effect on dopamine release in the striatum of the rat. Brain Res (2006) 0.77
Metal ion modulation of cystinyl aminopeptidase. Biochem J (2005) 0.77
Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor. Br J Pharmacol (2014) 0.77
Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis. J Med Chem (2011) 0.77
Adult cognitive ability and socioeconomic status as mediators of the effects of childhood disadvantage on salivary cortisol in aging adults. Psychoneuroendocrinology (2013) 0.76
Formation of angiotensin-(1-7) from angiotensin II by the venom of Conus geographus. Regul Pept (2002) 0.76
Amino triazolo diazepines (Ata) as constrained histidine mimics. Org Lett (2011) 0.76
Small potent ligands to the insulin-regulated aminopeptidase (IRAP)/AT(4) receptor. J Pept Sci (2007) 0.76
Non-competitive interaction between raclopride and spiperone on human D-receptors in intact Chinese hamster ovary cells. Fundam Clin Pharmacol (2009) 0.76
Selective labeling of IRAP by the tritiated AT(4) receptor ligand [3H]Angiotensin IV and its stable analog [3H]AL-11. Mol Cell Endocrinol (2009) 0.76
Corticotropin-releasing factor receptors induce calcium mobilization through cross-talk with Gq-coupled receptors. Eur J Pharmacol (2010) 0.76
Binding of "AT4 receptor" ligands to insulin regulated aminopeptidase (IRAP) in intact Chinese hamster ovary cells. Mol Cell Endocrinol (2011) 0.75
Conformational constraints in angiotensin IV to probe the role of Tyr², Pro⁵ and Phe⁶. J Pept Sci (2011) 0.75
In vitro effect of sanguinarine alkaloid on binding of [3H]candesartan to the human angiotensin AT1 receptor. Eur J Pharmacol (2003) 0.75
Genetic modulation of plasma NPY stress response is suppressed in substance abuse: association with clinical outcomes. Psychoneuroendocrinology (2011) 0.75
Reduced phase-advance of plasma melatonin after bright morning light in the luteal, but not follicular, menstrual cycle phase in premenstrual dysphoric disorder: an extended study. Chronobiol Int (2011) 0.75
[3H]IVDE77, a novel radioligand with high affinity and selectivity for the insulin-regulated aminopeptidase. Eur J Pharmacol (2013) 0.75
Angiotensin IV displays only low affinity for native insulin-regulated aminopeptidase (IRAP). Fundam Clin Pharmacol (2011) 0.75